Skip to Content

Charles River Laboratories International Inc CRL

Morningstar Rating
$204.46 +1.69 (0.83%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

Company Report

Charles River Earnings: Cautious Client Spending Affects Near Term, but Long-Term Outlook Positive

Charles River Laboratories reported third-quarter results highlighted by revenue of $1.03 billion, a 4% increase from the prior-year period. The company has experienced pressure from cautious client spending patterns. This has created headwinds for the research models and services segment as biopharma customers have reprioritized pipelines and are conserving cash amid macroeconomic challenges.

Price vs Fair Value

CRL is trading at a 21% discount.
Price
$204.46
Fair Value
$699.00
Uncertainty
Medium
1-Star Price
$874.00
5-Star Price
$468.00
Economic Moat
Gzpvs
Capital Allocation
Fcdczjwj

Bulls Say, Bears Say

Bulls

Charles River’s reputation for quality and scientific expertise supports its leading position in the research model and preclinical trial markets.

Bears

Charles River does not have a long-term advantage in drug discovery, as we believe that will remain the core competency of biotechnology and pharmaceutical companies.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRL is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$202.77
Day Range
$201.49204.95
52-Week Range
$161.65262.00
Bid/Ask
$203.87 / $204.98
Market Cap
$10.49 Bil
Volume/Avg
507,749 / 532,897

Key Statistics

Price/Earnings (Normalized)
18.31
Price/Sales
2.50
Dividend Yield
Dividend Yield (Forward)
Total Yield
0.23%

Company Profile

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Core
Total Number of Employees
21,400

Competitors

Valuation

Metric
CRL
ICLR
LH
Price/Earnings (Normalized)
18.3118.4414.66
Price/Book Value
3.172.502.34
Price/Sales
2.502.811.50
Price/Cash Flow
13.4619.4810.19
Price/Earnings
CRL
ICLR
LH

Financial Strength

Metric
CRL
ICLR
LH
Quick Ratio
0.961.140.96
Current Ratio
1.451.191.36
Interest Coverage
5.452.816.35
Quick Ratio
CRL
ICLR
LH

Profitability

Metric
CRL
ICLR
LH
Return on Assets (Normalized)
7.55%4.01%6.72%
Return on Equity (Normalized)
18.82%7.97%13.51%
Return on Invested Capital (Normalized)
10.91%7.30%9.13%
Return on Assets
CRL
ICLR
LH

Diagnostics & Research Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
TMO
Thermo Fisher Scientific IncClp$189.2 Bil
DHR
Danaher CorpCrgvmq$160.7 Bil
IDXX
IDEXX Laboratories IncQrtnyn$44.1 Bil
IQV
IQVIA Holdings IncNfgtyn$39.3 Bil
A
Agilent Technologies IncNxv$37.2 Bil
MTD
Mettler-Toledo International IncVrfvdc$23.6 Bil
ICLR
Icon PLCRhsdqp$22.4 Bil
LH
Laboratory Corp of America HoldingsHfjlzm$18.4 Bil
ILMN
Illumina IncFwzlnjx$17.9 Bil
WAT
Waters CorpFft$17.3 Bil